Meyka Pro banner
10x Genomics, Inc.

10x Genomics, Inc. (TXG) Stock Overview

Explore 10x Genomics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

TXGNASDAQ
HealthcareMedical - Healthcare Information Services
$46.27
$1.79(3.72%)
U.S. Market opens in 63h 26m

10x Genomics, Inc. (TXG)

Meyka AI Score

Z

Key Financials

Market Cap5.9B
P/E Ratio-274.68
EPS (TTM)$-0.17
ROE-0.03%
Fundamental Analysis

AI Price Forecasts

1 Month$43.87
3 Months$41.27
1 Year Target$15.94

TXG Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of 10x Genomics, Inc. (NASDAQ: TXG) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, 10x Genomics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of TXG on the NASDAQ shows an RSI of 66.53, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $15.94 for the NASDAQ listing.

Key metrics behind 10x Genomics, Inc.'s NASDAQ-traded stock include a P/E ratio of -274.68 and a market capitalization of 5.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TXG on the NASDAQ.

Price Performance (NASDAQ: TXG)

1-Day Change
-3.72%
5-Day Change
6.51%
1-Month Change
33.73%
3-Month Change
109.56%
6-Month Change
106.75%
Year-to-Date (YTD) Change
183.69%
1-Year Change
237.00%
3-Year Change
-22.70%
5-Year Change
-74.23%
All-Time (Max) Change
-12.28%

Contact Information

925 401 7300
6230 Stoneridge Mall Road, Pleasanton, CA, 94588-3260

Company Facts

11,780 Employees
IPO DateSep 12, 2019
CountryUS
Actively Trading

Frequently Asked Questions